VYGR [NASD]
Voyager Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own0.60% Shs Outstand38.51M Perf Week-0.98%
Market Cap349.38M Forward P/E- EPS next Y-0.83 Insider Trans-90.40% Shs Float32.93M Perf Month63.13%
Income-17.10M PEG- EPS next Q-0.55 Inst Own61.20% Short Float / Ratio3.33% / 4.04 Perf Quarter76.80%
Sales70.50M P/S4.96 EPS this Y-292.10% Inst Trans0.70% Short Interest1.10M Perf Half Y35.37%
Book/sh2.07 P/B4.38 EPS next Y3.40% ROA-8.70% Target Price9.40 Perf Year225.09%
Cash/sh3.42 P/C2.65 EPS next 5Y- ROE-22.00% 52W Range2.76 - 10.81 Perf YTD48.69%
Dividend- P/FCF38.82 EPS past 5Y-3.50% ROI- 52W High-16.13% Beta0.97
Dividend %- Quick Ratio2.00 Sales past 5Y21.30% Gross Margin- 52W Low228.62% ATR0.63
Employees101 Current Ratio2.00 Sales Q/Q-47.50% Oper. Margin-29.10% RSI (14)62.18 Volatility4.07% 9.90%
OptionableYes Debt/Eq0.00 EPS Q/Q166.90% Profit Margin-24.20% Rel Volume1.08 Prev Close9.01
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume271.79K Price9.07
Recom2.30 SMA2010.75% SMA5034.74% SMA20041.93% Volume293,146 Change0.67%
Oct-07-21Upgrade Robert W. Baird Neutral → Outperform $6 → $9
Feb-26-21Downgrade Robert W. Baird Outperform → Neutral $18 → $6
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Show Previous Ratings
Jan-27-23 07:00AM
Jan-24-23 04:01PM
06:15AM
Jan-20-23 12:08PM
09:55AM
01:23PM Loading…
Jan-09-23 01:23PM
09:15AM
08:15AM
07:00AM
Jan-04-23 07:00AM
Dec-21-22 06:57AM
Dec-14-22 07:00AM
Nov-29-22 04:01PM
Nov-10-22 05:26AM
Nov-08-22 08:25AM
07:00AM Loading…
07:00AM
Nov-01-22 07:30AM
Oct-27-22 10:02AM
Oct-25-22 10:01AM
Oct-18-22 04:01PM
Oct-14-22 08:34AM
Oct-11-22 07:00AM
Oct-04-22 11:34AM
07:00AM
Oct-03-22 07:00AM
06:26AM
Sep-27-22 07:00AM
Sep-22-22 04:01PM
Sep-07-22 07:30AM
Aug-05-22 11:13AM
05:15PM Loading…
Aug-04-22 05:15PM
04:01PM
Aug-03-22 11:30AM
Aug-02-22 04:01PM
Jul-28-22 07:00AM
Jun-09-22 03:23PM
May-19-22 08:38AM
06:00AM
May-16-22 06:00AM
May-04-22 05:35PM
04:01PM
01:22PM
May-03-22 07:00AM
May-02-22 11:04AM
Apr-25-22 02:51PM
Apr-22-22 01:19PM
11:36AM
Apr-21-22 07:28AM
Apr-20-22 10:19AM
Apr-18-22 12:45PM
Apr-12-22 02:57PM
11:57AM
11:47AM
Apr-08-22 12:26PM
11:39AM
Apr-07-22 02:50PM
Apr-06-22 12:08PM
11:58AM
Apr-01-22 12:00PM
Mar-30-22 07:43AM
Mar-26-22 06:11AM
Mar-23-22 11:40AM
08:42AM
08:28AM
Mar-22-22 10:52AM
09:07AM
07:00AM
Mar-19-22 06:05AM
Mar-17-22 09:47AM
Mar-15-22 11:13AM
10:52AM
10:00AM
Mar-10-22 02:31PM
12:27PM
Mar-09-22 12:54PM
12:35PM
Mar-08-22 02:20PM
08:30AM
06:27AM
06:16AM
01:15AM
Mar-07-22 09:15AM
Mar-01-22 05:55PM
Feb-22-22 04:35AM
Feb-17-22 03:03PM
Feb-10-22 07:00AM
Feb-03-22 07:00AM
Jan-26-22 05:15PM
Dec-14-21 01:25PM
Nov-19-21 07:30AM
Nov-17-21 03:01AM
Nov-16-21 07:00AM
Nov-02-21 08:25AM
07:00AM
Nov-01-21 03:02PM
Oct-20-21 08:54AM
Oct-14-21 11:30AM
Oct-07-21 12:55PM
10:23AM
08:30AM
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Third Rock Ventures III, L.P.10% OwnerJan 25Sale9.2250,000461,0005,123,933Jan 26 05:23 PM
Third Rock Ventures III, L.P.10% OwnerJan 24Sale9.27100,000927,0005,173,933Jan 26 05:23 PM
Third Rock Ventures III, L.P.10% OwnerJan 23Sale9.0655,000498,3005,273,933Jan 24 06:20 PM
Third Rock Ventures III, L.P.10% OwnerJan 20Sale9.15100,000915,0005,328,933Jan 24 06:20 PM
Hesslein Robert W.Senior VP & General CounselJan 17Sale9.852,18821,549112,775Jan 19 04:57 PM
Carter Todd AlfredChief Scientific OfficerJan 17Sale9.851,10610,89235,088Jan 19 04:55 PM
Swartz RobinChief Operating OfficerJan 17Sale9.852,18821,54951,903Jan 19 04:53 PM
EcoR1 Capital, LLC10% OwnerJan 11Sale8.50110,000934,6153,851,507Jan 11 06:26 PM
EcoR1 Capital, LLC10% OwnerJan 10Sale8.05336,4002,709,4333,961,507Jan 11 06:26 PM
EcoR1 Capital, LLC10% OwnerJan 09Sale7.67456,0003,498,2954,297,907Jan 11 06:26 PM
Carter Todd AlfredChief Scientific OfficerJan 06Sale6.413882,48736,194Jan 10 04:07 PM
Third Rock Ventures III, L.P.10% OwnerAug 25Sale6.22200,0001,244,0005,428,933Aug 26 04:15 PM
Third Rock Ventures III, L.P.10% OwnerAug 24Sale6.09149,972913,3295,628,933Aug 26 04:15 PM
Third Rock Ventures III, L.P.10% OwnerAug 16Sale6.04128,456775,8745,778,905Aug 18 04:15 PM
Third Rock Ventures III, L.P.10% OwnerAug 15Sale6.04135,808820,2805,907,361Aug 16 04:22 PM
Third Rock Ventures III, L.P.10% OwnerAug 12Sale6.12348,0072,129,8036,043,169Aug 16 04:22 PM
PIERCE GLENNDirectorJul 14Sale6.709,51263,73016,788Jul 18 05:34 PM
Higgins Michael JDirectorJul 14Sale6.7013,89193,07031,314Jul 18 05:32 PM
EcoR1 Capital, LLC10% OwnerJun 23Buy5.66376,0002,126,5434,753,907Jun 23 05:21 PM
EcoR1 Capital, LLC10% OwnerJun 21Buy5.28101,400535,5044,377,907Jun 23 05:21 PM
Swartz RobinChief Operating OfficerApr 04Sale8.251,52712,59852,060Apr 06 04:34 PM
Hesslein Robert W.Senior VP & General CounselApr 04Sale8.252,78622,984114,963Apr 06 04:34 PM
Swartz RobinChief Operating OfficerMar 21Sale8.294,41336,60453,587Mar 23 06:40 PM
Hesslein Robert W.Senior VP & General CounselMar 21Sale8.294,95541,100117,749Mar 23 06:39 PM
Burek JulieVP, FinanceMar 21Sale8.292,64921,97252,458Mar 23 06:36 PM
Burek JulieVP, FinanceFeb 17Sale3.557892,80155,107Feb 22 04:35 PM
Hesslein Robert W.Senior VP & General CounselFeb 17Sale3.554,10014,555122,704Feb 22 04:37 PM
Hesslein Robert W.Senior VP & General CounselFeb 11Sale3.363,25210,927126,804Feb 15 04:42 PM
Burek JulieVP, FinanceFeb 11Sale3.363611,21355,896Feb 15 04:40 PM